Home
Search
Logo
Search

Enanta Pharmaceuticals

Enanta Pharmaceuticals

+10

Neumora's Phase 3 Trial Miss and a Trio of VC Raises

Jun 23, 2026

•

3 min read

Neumora's Phase 3 Trial Miss and a Trio of VC Raises

Watertown companies have now raised $245 million in VC funds in 2026

Sam Ghilardi
Sam Ghilardi

Enanta Pharmaceuticals

+6

Watertown's First Potential IPO since 2023, Remix's Positive Clinical Trial Results, and Triveni Jumps into the Eczema Market

May 26, 2026

•

3 min read

Watertown's First Potential IPO since 2023, Remix's Positive Clinical Trial Results, and Triveni Jumps into the Eczema Market

Plus the Boston Business Journal covers the rise of Watertown's Biotech scene, and more

Sam Ghilardi
Sam Ghilardi

Empress Therapeutics

+7

Triveni's New Digs, 99 Coolidge's Tenant Bonanza, and Remix's FDA Fast Track Designation

Mar 31, 2026

•

8 min read

Triveni's New Digs, 99 Coolidge's Tenant Bonanza, and Remix's FDA Fast Track Designation

Plus Addgenes' new partnership, and Neumora and Acrivon's cash flow updates

Sam Ghilardi
Sam Ghilardi

Enanta Pharmaceuticals

+16

Labshares Expanding to Watertown

Nov 18, 2025

•

8 min read

Labshares Expanding to Watertown

Neumora's Wegovy alternative, Dyno announces manufacturing pact, and more

Sam Ghilardi
Sam Ghilardi

Enanta Pharmaceuticals

+7

Watertown Bio Journal Club - How Many Ways Can You Break a Protein?

Nov 11, 2025

•

6 min read

Watertown Bio Journal Club - How Many Ways Can You Break a Protein?

Talking about proteases, PROTACs, and molecular glues. Plus new methods for mass spec tagging, viral inhibitors, and more.

Sam Ghilardi
Sam Ghilardi

Enanta Pharmaceuticals

+12

Welcome to Watertown Bio

Nov 4, 2025

•

8 min read

Welcome to Watertown Bio

Soufflé Therapeutics Launches from Stealth, Disc and Werewolf receive FDA priority, Affini-T may be winding down.

Sam Ghilardi
Sam Ghilardi

Subscribe to Watertown Bio

Get the top Watertown Biotech news delivered straight to your inbox.

© 2026 Watertown Bio.
beehiivPowered by beehiiv